Cochrane · systematic review · CD001416
Zonisamide add‐on therapy for focal epilepsy
Brigo, F, Lattanzi, S, Igwe, SC, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyZonisamide compared to placebo for focal epilepsy
Population: patients with focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% responder rate (whole treatment period; any dose) Zonisamide vs placebo | RR 1.86 [1.6, 2.17] | 7 studies · 1429 participants | Moderate Downgraded: risk of bias |
Withdrawal rates (whole treatment period; any dose) Zonisamide vs placebo | RR 1.44 [1.08, 1.93] | 6 studies · 1156 participants | Moderate Downgraded: risk of bias |
Adverse effects: ataxia (whole treatment period; any dose) Zonisamide vs placebo | RR 3.85 | 4 studies · 734 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: dizziness (whole treatment period; any dose) Zonisamide vs placebo | RR 1.4 | 7 studies · 1429 participants | Moderate Downgraded: risk of bias |
Adverse effects: fatigue (whole treatment period; any dose) Zonisamide vs placebo | RR 1.41 | 6 studies · 1045 participants | Moderate Downgraded: risk of bias |
Adverse effects: nausea (whole treatment period; any dose) Zonisamide vs placebo | RR 1.1 | 5 studies · 805 participants | Moderate Downgraded: risk of bias |
Adverse effects: somnolence (whole treatment period; any dose) Zonisamide vs placebo | RR 1.52 | 8 studies · 1636 participants | Moderate Downgraded: risk of bias |
Zonisamide compared to placebo for focal epilepsy
Population: patients with focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% responder rate ‐ whole treatment period ‐ Any dose Zonisamide vs placebo | RR 1.86 [1.6, 2.17] | 7 studies · 1429 participants | Moderate Downgraded: risk of bias |
Withdrawal rates ‐ Any dose Zonisamide vs placebo | RR 1.44 [1.08, 1.93] | 6 studies · 1156 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ Ataxia Zonisamide vs placebo | RR 3.85 [1.36, 10.93] | 4 studies · 734 participants | Low Downgraded: risk of bias |
Adverse effects ‐ Dizziness Zonisamide vs placebo | RR 1.4 [0.9, 2.18] | 7 studies · 1429 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ Fatigue Zonisamide vs placebo | RR 1.41 [0.79, 2.53] | 6 studies · 1045 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ Nausea Zonisamide vs placebo | RR 1.1 [0.58, 2.1] | 5 studies · 805 participants | Moderate Downgraded: risk of bias |
Adverse effects ‐ Somnolence Zonisamide vs placebo | RR 1.52 [1, 2.31] | 8 studies · 1636 participants | Moderate Downgraded: risk of bias |
Zonisamide versus placebo for drug‐resistant partial epilepsy
Population: patients with drug‐resistant partial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% responder rate ‐ whole treatment period ‐ any dose Zonisamide vs placebo | RR 1.92 [1.52, 2.42] | 5 studies · 949 participants | High |
Withdrawal rates ‐ any dose Zonisamide vs placebo | RR 1.47 [1.07, 2.01] | 5 studies · 949 participants | High |
Adverse effects ‐ ataxia Zonisamide vs placebo | no estimate extracted | 3 studies · 494 participants | High |
Adverse effects ‐ dizziness Zonisamide vs placebo | no estimate extracted | 5 studies · 949 participants | High |
Adverse effects ‐ nausea Zonisamide vs placebo | no estimate extracted | 4 studies · 598 participants | High |
Adverse effects ‐ fatigue Zonisamide vs placebo | no estimate extracted | 4 studies · 598 participants | High |
Adverse effects ‐ somnolence Zonisamide vs placebo | no estimate extracted | 5 studies · 949 participants | High |
Adverse effects ‐ agitation/irritability Zonisamide vs placebo | no estimate extracted | 4 studies · 598 participants | High |
Adverse effects ‐ anorexia Zonisamide vs placebo | no estimate extracted | 3 studies · 494 participants | High |